Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Formulation and In Vivo Evaluation of Ticagrelor Self-nanoemulsifying Drug Delivery Systems

Author(s): Adella Aparna*, Yamsani Shravan Kumar and Darna V.R.N. Bhikshapathi

Volume 9, Issue 1, 2021

Published on: 08 July, 2020

Page: [61 - 69] Pages: 9

DOI: 10.2174/2211738508666200708150151

Price: $65

Abstract

Background: Ticagrelor (TGR), being an antiplatelet agent, belongs to BCS class IV drug with low solubility and permeability that undergoes first-pass metabolism, leading to reduced bioavailability of 36%.

Objective: The main objective of this study is to develop TGR SNEDDS for enhancing solubility and oral bioavailability.

Methods: An oil, surfactant and co-surfactant (miglyol 810, brij 35 and lauro glycol FCC) are chosen based on the maximum solubility of TGR. The selected vehicles are mixed in different ratios and are agitated mildly. Transmittance values that are more than 80 were noted and are used for constructing pseudo ternary phase diagram. Formulations that passed stability testing were evaluated for % transmission, drug content and in vitro drug release analysis. In vivo bioavailability studies of optimized SNEDDS are performed in Wistar rats.

Results: From evaluation studies of TGR, formulation F13 with maximum drug release of 98.99% in 60 minutes, that is higher than 31.99% of the pure drug is considered as an optimised formulation. The particle size, Z average and zeta potential of the optimized TGR formulation F13 was 289.6 nm, 185.1 nm and -18.3 mV respectively. The FTIR and SEM studies do not indicate any drug excipient interaction and confirm nano size which is stable for 3 months. From in vivo bioavailability studies in rats, the Cmax of optimized TGR SNEDDS (302.43±4.78 ng/ml) is higher than pure TGR suspension (47.32±2.75 ng/ml) and optimized SNEDDS exhibited 5 folds increase in oral bioavailability when compared to pure drug.

Conclusion: Hence the results reveal that, application of SNEDDS formulation technique for TGR Increases solubility and oral bioavailability.

Keywords: Ticagrelor, myocardial infarction, SNEDDS, solubility, in vivo bioavailability studies, thrombosis.

« Previous Next »
Graphical Abstract

[1]
Hollopeter, G.; Jantzen, H.M.; Vincent, D.; Li, G.; England, L.; Ramakrishnan, V.; Yang, R.B.; Nurden, P.; Nurden, A.; Julius, D.; Conley, P.B. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature, 2001, 409(6817), 202-207.[http://dx.doi.org/10.1038/35051599] [PMID: 11196645]
[2]
Bambace, N.M.; Levis, J.E.; Holmes, C.E. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets, 2010, 21(2), 85-93.[http://dx.doi.org/10.3109/09537100903470298] [PMID: 20063989]
[3]
Beigi, R.; Kobatake, E.; Aizawa, M.; Dubyak, G.R. Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am. J. Physiol., 1999, 276(1), C267-C278.[http://dx.doi.org/10.1152/ajpcell.1999.276.1.C267] [PMID: 9886943]
[4]
Cattaneo, M.; Schulz, R.; Nylander, S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J. Am. Coll. Cardiol., 2014, 63(23), 2503-2509.[http://dx.doi.org/10.1016/j.jacc.2014.03.031] [PMID: 24768873]
[5]
Wijeyeratne, Y.D.; Joshi, R.; Heptinstall, S. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes. Expert Rev. Clin. Pharmacol., 2012, 5(3), 257-269.[http://dx.doi.org/10.1586/ecp.12.17] [PMID: 22697589]
[6]
Yeom, D.W.; Song, Y.S.; Kim, S.R.; Lee, S.G.; Kang, M.H.; Lee, S.; Choi, Y.W. Development and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design. Int. J. Nanomedicine, 2015, 10, 3865-3877.[PMID: 26089663]
[7]
Yeom, D.W.; Chae, B.R.; Son, H.Y.; Kim, J.H.; Chae, J.S.; Song, S.H.; Oh, D.; Choi, Y.W. Enhanced oral bioavailability of valsartan using a polymer-based supersaturable self-microemulsifying drug delivery system. Int. J. Nanomedicine, 2017, 12, 3533-3545.[http://dx.doi.org/10.2147/IJN.S136599] [PMID: 28507434]
[8]
Hosseini, M.H.; Alizadeh, N.; Khanchi, A.R. Effect of menthol as solid cosolvent on the solubility enhancement of clozapine and lamorigine in supercritical CO2. J. Supercrit. Fluids, 2010, 55, 14-22.[http://dx.doi.org/10.1016/j.supflu.2010.09.002]
[9]
Patel, G.; Shelat, P.; Lalwani, A. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment. Drug Deliv., 2016, 23(8), 3027-3042.[http://dx.doi.org/10.3109/10717544.2016.1141260] [PMID: 26882014]
[10]
Wang, L.; Dong, J.; Chen, J.; Eastoe, J.; Li, X. Design and optimization of a new self-nanoemulsifying drug delivery system. J. Colloid Interface Sci., 2009, 330(2), 443-448.[http://dx.doi.org/10.1016/j.jcis.2008.10.077] [PMID: 19038395]
[11]
Vanita, S.S.; Subhashini, N.J.P. Novel self-nanoemulsion drug delivery system of fenofibrate with improved bio-availability. Int. J. Pharma Bio Sci., 2013, 4(2), 511-521.
[12]
Nekkanti, V.; Wang, Z.; Betageri, G.V. Pharmacokinetic evaluation of improved oral bioavailability of valsartan: Proliposomes versusself-nanoemulsifying drug delivery system. AAPS PharmSciTech, 2016, 17(4), 851-862.[http://dx.doi.org/10.1208/s12249-015-0388-8] [PMID: 26381913]
[13]
Rajinikanth, P.S.; Neo, W.K.; Sanjay, G. Self-nanoemulsifyingdrug delivery systems of Valsartan: Preparation and in vitro characterization. Int. J. Drug Deliv., 2012, 4(2), 153-163.
[14]
Gurjeet, K.; Pankaj, C.; Harikumar, S.L. Formulation development of self nanoemulsifying drug delivery system (SNEDDS) of celecoxib for improvement of oral bioavailability. Pharmacophore, 2013, 4(4), 120-133.
[15]
Zhang, J.; Peng, Q.; Shi, S.; Zhang, Q.; Sun, X.; Gong, T.; Zhang, Z. Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex. Int. J. Nanomedicine, 2011, 6, 3405-3414.[PMID: 22267925]
[16]
Delma, D. CruzanuBabu, EenaJoshy. Bioanalytical Method Development and Validation of TGR by RP-HPLC. Int. J. App. Pharm., 2017, 9(3), 51-54.[http://dx.doi.org/10.22159/ijap.2017v9i3.17452]

Rights & Permissions Print Cite
Article Metrics
28
1
© 2024 Bentham Science Publishers | Privacy Policy